RXI Pharma (RXII) Announces Completion of 30-Day RXI-109 IND Review
Tweet Send to a Friend
RXI Pharma (NASDAQ: RXII) announced that the 30-day review period following the filing of the Company's Investigational New Drug (IND) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
